|
Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): A validation study within the NIVOREN GETUG-AFU 26 translational study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; IPSEN; Pfizer |
Consulting or Advisory Role - Ipsen; Janssen Oncology |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen; Oncorena; Pfizer |
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Ipsen; Oncorena; Pfizer |
Research Funding - BMS France (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bellerophon Theraeutics (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - BMS; MSD |
|
|
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche (Inst); Sanofi (Inst) |